Debtset – Bailiff-Sheriff Aust MEMBER Login
Novogen gains Aust. patents on potential cancer treatment drugs
US-AUSTRALIAN drug discovery company, Novogen Limited, which is listed on both the ASX and NASDAQ, has announced a breakthrough, with its patent for the superbenzopyran (SBP) drug family being granted in Australia for the potential treatment of cancerous tumours.
This patent covers Novogen’s lead SBP candidates Cantrixil and Trilexium and it provides full protection for Novogen’s intellectual property (IP) for the SBP family until 2035. 
Novogen’s three lead molecules Cantrixil, Anisina, and Trilexium, are in advanced preclinical development for various cancer types, with the most advanced molecule, Cantrixil, slated to enter clinical trials in the second half of 2016.
In addition, the key patent application covering the first lead anti-tropomyosin (ATM) compound, Anisina, has been examined and accepted by the Australian Patent Office. The application has now entered the standard three-month opposition window prior to being granted.
According to Novogen North America CEO, Dr Andrew Heaton, these milestones help validate the company's discovery platforms and represent critical milestones in IP protection.
“The SBP patent covers a wide range of new chemical entities, including Cantrixil and Trilexium,” Dr Heaton said. “Critically, the patent covers composition of matter, a new abridged method of manufacture, and treatment for a wide variety of cancer types.
“Our key SBP assets are now fully covered in Australia. Furthermore, passing scrutiny in Australia will aid the ongoing global roll-out of this patent.” 
“The availability of the Global Patent Prosecution Highway will permit accelerated examination in overseas jurisdictions, based on acceptance of an Australian application. This provides an opportunity to expedite examination and subsequent patent grant of SBP and ATM applications in a number of key overseas jurisdictions, such as the United States, Japan and Korea,” he said.
Cantrixil has completed the necessary toxicology studies in readiness for the first human trials.
ends
